These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 3031627)

  • 21. Phthalazine PDE IV inhibitors: conformational study of some 6-methoxy-1,4-disubstituted derivatives.
    Haack T; Fattori R; Napoletano M; Pellacini F; Fronza G; Raffaini G; Ganazzoli F
    Bioorg Med Chem; 2005 Jul; 13(14):4425-33. PubMed ID: 15927474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors.
    Rutten K; Prickaerts J; Hendrix M; van der Staay FJ; Sik A; Blokland A
    Eur J Pharmacol; 2007 Mar; 558(1-3):107-12. PubMed ID: 17207788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition by 2- or/and 8-substituted adenosine derivatives of adenosine deaminase and calmodulin-dependent phosphodiesterase.
    Sasaki Y; Ono Y
    Nucleic Acids Symp Ser; 1980; (8):s163-6. PubMed ID: 6265879
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pharmacologic value of cyclic nucleotide phosphodiesterase inhibitors].
    Nemoz G; Prigent AF
    Ann Pharm Fr; 1984; 42(2):99-112. PubMed ID: 6091520
    [No Abstract]   [Full Text] [Related]  

  • 26. [Phosphodiesterase inhibitor: griseolic acid, its' derivatives and their biological activities].
    Kaneko M; Yamazaki M
    Tanpakushitsu Kakusan Koso; 1995 Jul; 40(10):1268-76. PubMed ID: 7568925
    [No Abstract]   [Full Text] [Related]  

  • 27. Comparison of different heterocyclic scaffolds as substrate analog PDE5 inhibitors.
    Haning H; Niewöhner U; Schenke T; Lampe T; Hillisch A; Bischoff E
    Bioorg Med Chem Lett; 2005 Sep; 15(17):3900-7. PubMed ID: 15993055
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Ca2+-calmodulin-activated cyclic nucleotide phosphodiesterase from the soluble fraction of the human brain: Kinetic properties and the effect of the antidepressant pyrazidol and its nitro analog on the enzyme].
    Medvedeva MV; Belov AA; Kireeva NN; Bobruskin ID
    Biokhimiia; 1993 May; 58(5):798-808. PubMed ID: 8393348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.
    Mushlin P; Boerth RC; Wells JN
    Mol Pharmacol; 1981 Jul; 20(1):179-89. PubMed ID: 6270531
    [No Abstract]   [Full Text] [Related]  

  • 30. Synthesis and cyclic GMP phosphodiesterase inhibitory activity of a series of 6-phenylpyrazolo[3,4-d]pyrimidones.
    Dumaître B; Dodic N
    J Med Chem; 1996 Apr; 39(8):1635-44. PubMed ID: 8648603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2,1,3-Benzothiadiazine derivatives: synthesis and screening versus PDE4 enzyme.
    Tait A; Luppi A; Avallone R; Baraldi M
    Farmaco; 2005 Aug; 60(8):653-63. PubMed ID: 15963514
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Griseolic acids B and C, an inhibitor of cyclic adenosine 3',5'-monophosphate phosphodiesterase.
    Takahashi S; Nakagawa F; Sato S
    J Antibiot (Tokyo); 1988 May; 41(5):705-6. PubMed ID: 2838447
    [No Abstract]   [Full Text] [Related]  

  • 33. Synthesis, biological evaluation and molecular modelling studies on benzothiadiazine derivatives as PDE4 selective inhibitors.
    Tait A; Luppi A; Hatzelmann A; Fossa P; Mosti L
    Bioorg Med Chem; 2005 Feb; 13(4):1393-402. PubMed ID: 15670947
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PDE5 inhibitors: An original access to novel potent arylated analogues of tadalafil.
    Beghyn T; Hounsou C; Deprez BP
    Bioorg Med Chem Lett; 2007 Feb; 17(3):789-92. PubMed ID: 17107795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cyclic nucleotide phosphodiesterases and human arterial smooth muscle cell proliferation.
    Rybalkin SD; Bornfeldt KE
    Thromb Haemost; 1999 Aug; 82(2):424-34. PubMed ID: 10605733
    [No Abstract]   [Full Text] [Related]  

  • 36. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pharmacodynamic aspects of theophylline].
    Marmo E
    Clin Ter; 1983 Jul; 106(2):87-94. PubMed ID: 6313282
    [No Abstract]   [Full Text] [Related]  

  • 38. Design and synthesis of novel imidazo[1,2-a]quinoxalines as PDE4 inhibitors.
    Deleuze-Masquéfa C; Gerebtzoff G; Subra G; Fabreguettes JR; Ovens A; Carraz M; Strub MP; Bompart J; George P; Bonnet PA
    Bioorg Med Chem; 2004 Mar; 12(5):1129-39. PubMed ID: 14980625
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spectral and conformational analysis of deoxyadenosine adducts derived from syn- and anti-Dibenzo[a,l]pyrene diol epoxides: fluorescence studies.
    Jankowiak R; Lin CH; Zamzow D; Roberts KP; Li KM; Small GJ
    Chem Res Toxicol; 1999 Sep; 12(9):768-77. PubMed ID: 10490497
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The discovery of tadalafil: a novel and highly selective PDE5 inhibitor. 2: 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4-dione analogues.
    Daugan A; Grondin P; Ruault C; Le Monnier de Gouville AC; Coste H; Linget JM; Kirilovsky J; Hyafil F; Labaudinière R
    J Med Chem; 2003 Oct; 46(21):4533-42. PubMed ID: 14521415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.